ChitogenX Inc. (CHNXF) 株価予測

ChitogenX, Inc. is a clinical stage biotech company, which engages in the development of therapeutic soft tissue repair technologies for orthopaedic and sports medicine surgeries. The company is headquartered in Kirkland, Quebec. The company went IPO on 2017-10-10. The firm is engaged in the development of therapeutic tissue repair technologies to improve tissue healing. The firm is committed to the clinical development of its proprietary RESTORE technology platform, a muco-adhesive CHITOSAN based biopolymer matrix, specifically designed to deliver biologics such as platelet-rich plasma (PRP) or bone marrow aspirate concentrate (BMAC), to enhance healing in various musculoskeletal conditions. Ortho-R, its lead Chitosan-PRP hybrid biologic implant combination product, is formulated and designed to increase the healing rates of occupational and sports related injuries to tendons, ligaments, and cartilage such as the meniscus. Its other formulations are being developed to leverage the technology's performance characteristics, such as tissue adhesion, pliability, and ability to deliver biologics or therapeutics to various tissues damaged by trauma or disease.